---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-24-000067"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:16:23.610873+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Agios Q1 2024 PYRUKYND revenue $8.2M; net loss $81.5M; mitapivat ENERGIZE-T readout Q2

## Summary
- PYRUKYND net revenue $8.2M in Q1 2024, up 15% sequentially; 120 patients on therapy.
- Net loss $81.5M in Q1 2024 vs $81.0M in Q1 2023; cash $714.3M as of March 31, 2024.
- Positive Phase 3 ENERGIZE results for mitapivat in non-transfusion-dependent thalassemia announced in January.
- ENERGIZE-T topline data expected Q2 2024; FDA filing for mitapivat in thalassemia planned year-end.
- Servier's vorasidenib NDA accepted with PDUFA Aug 20, 2024; Agios eligible for $200M milestone and 15% royalties.

## SEC filing metadata
- accession: 0001439222-24-000067
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922224000067/0001439222-24-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922224000067/agio-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-24-000067
- JSON: https://secwatch.observer/filing/0001439222-24-000067.json
- Plain text: https://secwatch.observer/filing/0001439222-24-000067.txt

## Key facts
- Earnings Releases
  AGIOS PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2024 results: revenue $8.2 million.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $8.2 million
  - Result: reported results
  source text: RISE UP Study in Sickle Cell Disease, ACTIVATE-KIDS and ACTIVATE KIDS-T in Pediatric PK Deficiency, All Expected by End of 2025 – – PYRUKYND® (Mitapivat) Net Revenue of $8.2 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $714.3 Million as of March 31, 2024 – CAMBRIDGE, Mass., May 2, 2024 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000143922224000067/0001439222-24-000067-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.